Frequent expression of cd99 in anaplastic large cell lymphoma a clinicopathologic and immunohistochemical study of 160 cases

American Journal of Clinical Pathology

Volumn 131, Issue 4, 2009, Pages 574-579

  Buxton, Daniel ^a   Bacchi, Carlos E ^b   Gualco, Gabriela ^b   Weiss, Lawrence M ^c   Zuppan, Craig W ^a   Rowsell, Edward H ^a   Huang, Qin ^c   Wang, Jun ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Consultoria em Patologia ^*  (Brazil)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Anaplastic large cell lymphoma; CD99; HBA 71; HO36 1.1; Immunohistochemistry; MIC2; O13; Tissue microarray

Indexed keywords

CD99 ANTIGEN; PEROXIDASE; ANAPLASTIC LYMPHOMA KINASE; CD99 PROTEIN, HUMAN; CELL ADHESION MOLECULE; LEUKOCYTE ANTIGEN; PROTEIN TYROSINE KINASE; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CHILD; DIFFERENTIAL DIAGNOSIS; EWING SARCOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; IMMUNOREACTIVITY; LARGE CELL LYMPHOMA; MALE; PATHOLOGY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN DEFECT; TISSUE MICROARRAY; BIOSYNTHESIS; INFANT; METABOLISM; MIDDLE AGED; PRESCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CELL ADHESION MOLECULES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MALE; MIDDLE AGED; PROTEIN-TYROSINE KINASES; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 65349168387     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPE68HZXCGWTKK     Document Type: Article

References (36)

1. Hamilton G, Fellinger EJ, Schratter I, et al. Characterization of a human endocrine tissue and tumor-associated Ewing's sarcoma antigen. Cancer Res. 1988;48:6127-6131.
2. Jung KC, Park WS, Bae YM, et al. Immunoreactivity of CD99 in stomach cancer. J Korean Med Sci. 2002;17:483-489.
3. Milanezi F, Pereira EM, Ferreira FV, et al. CD99/MIC-2 surface protein expression in breast carcinomas. Histopathology. 2001;39:578-583.
4. Yoo SH, Han J, Kim TJ, et al. Expression of CD99 in pleomorphic carcinomas of the lung. J Korean Med Sci. 2005;20:50-55.
5. Choi Y-L, Kim H-S, Ahn G. Immunoexpression of inhibin a subunit, inhibin/activin PA subunit and CD99 in ovarian tumors. Arch Pathol Lab Med. 2000;124:563-569.
6. Gordon MD, Corless C, Renshaw AA, et al. CD99, keratin, and vimentin staining of sex cord-stromal tumors, normal ovary, and testis. Mod Pathol. 1998;11:769-773.
7. Kommoss F, Oliva E, Bittinger F, et al. Inhibin-alpha CD99, HEA125, PLAP, and chromogranin immunoreactivity in testicular neoplasms and the androgen insensitivity syndrome. Hum Pathol. 2000;31:1055-1061.
8. Matias-Guiu X, Pons C, Prat J. Mullerian inhibiting substance, alpha-inhibin, and CD99 expression in sex cord-stromal tumors and endometrioid ovarian carcinomas resembling sex cord-stromal tumors. Hum Pathol. 1998;29:840-845.
9. Hartel PH, Fanburg-Smith JC, Frazier AA, et al. Primary pulmonary and mediastinal synovial sarcoma: a clinicopathologic study of 60 cases and comparison with five prior series. Mod Pathol. 2007;20:760-769.
10. Machen SK, Fisher C, Gautam RS, et al. Utility of cytokeratin subsets for distinguishing poorly differentiated synovial sarcoma from peripheral primitive neuroectodermal tumour. Histopathology. 1998;33:501-507.
11. Pan Y, Liu WP, Li JF, et al. A clinicopathological study of 96 cases of lymphoblastic lymphoma [in Chinese]. Zhonghua Xue Ye Xue Za Zhi. 2005;26:218-222.
12. Riopel M, Dickman PS, Link MP, et al. MIC2 analysis in pediatric lymphomas and leukemias. Hum Pathol. 1994;25:396-399.
13. Robertson PB, Neiman RS, Worapongpaiboon S, et al. O13 (CD99) positivity in hematologic proliferations correlates with TdT positivity. Mod Pathol. 1997;10:277-282.
14. Zhang PJ, Barcos M, Stewart CC, et al. Immunoreactivity of MIC2 (CD99) in acute myelogenous leukemia and related diseases. Mod Pathol. 2000;13:452-458.
15. Sung CO, Ko YH, Park S, et al. Immunoreactivity of CD99 in non-Hodgkin's lymphoma: unexpected frequent expression in ALK-positive anaplastic large cell lymphoma. J Korean Med Sci. 2005;20:952-956.
16. Gurevich J, Wiliams SG, Polzer J, et al. The pattern of CD99 expression in pediatric lymphoid neoplasms [abstract]. Mod Pathol. 2008;21(suppl 1):256A.
17. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008. WHO Classification of Tumours; vol 2.
18. Stein H, Foss HD, Durkop H, et al. CD30+ anaplastic large cell lymphoma: a review of its histologic, genetic, and clinical features. Blood. 2000;96:3681-3695.
19. George DH, Scheithauer BW, Aker FV, et al. Primary anaplastic large cell lymphoma of the central nervous system: prognostic effect of ALK-1 expression. Am J Surg Pathol. 2003;27:487-493.
20. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1995;267:316-317.
21. Goodfellow PJ, Darling SM, Thomas NS, et al. A pseudoautosomal gene in man. Science. 1986;234:740-743.
22. Bernard G, Breittmayer JP, de Matteis M, et al. Apoptosis of immature thymocytes mediated by E2/CD99. J Immunol. 1997;158:2543-2550.
23. Kim MK, Choi YL, Kim MK, et al. MHC class II engagement inhibits CD99-induced apoptosis and up-regulation of T cell receptor and MHC molecules in human thymocytes and T cell line. FEBS Lett. 2003;546:379-384.
24. Schenkel AR, Mamdouh Z, Chen X, et al. CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat Immunol. 2002;3:143-150.
25. Dworzak MN, Fritsch G, Buchinger P, et al. Flow cytometric assessment of human MIC2 expression in bone marrow, thymus, and peripheral blood. Blood. 1994;83:415-425.
26. Imbert AM, Belaaloui G, Bardin F, et al. CD99 expressed on human mobilized peripheral blood CD34+ cells is involved in transendothelial migration. Blood. 2006;108:2578-2586.
27. Park CK, Shin YK, Kim TJ, et al. High CD99 expression in memory T and B cells in reactive lymph nodes. J Korean Med Sci. 1999;14:600-606.
28. Choi YL, Chi JG, Suh YL. CD99 immunoreactivity in ependymoma. Appl Immunohistochem Mol Morphol. 2001;9:125-129.
29. Kreppel M, Aryee DN, Schaefer KL, et al. Suppression of KCMF1 by constitutive high CD99 expression is involved in the migratory ability of Ewing's sarcoma cells. Oncogene. 2006;25:2795-2800.
30. Lee EJ, Lee HG, Park SH, et al. CD99 type II is a determining factor for the differentiation of primitive neuroectodermal cells. Exp Mol Med. 2003;35:438-447.
31. Granter SR, Renshaw AA, Fletcher CD, et al. CD99 reactivity in mesenchymal chondrosarcoma. Hum Pathol. 1996;27:1273-1276.
32. de Saint-Aubain SN, Rubin BP, Fletcher CD. Myxoid solitary fibrous tumor: a study of seven cases with emphasis on differential diagnosis. Mod Pathol. 1999;12:463-471.
33. Alsaad KO, Serra S, Perren A, et al. CK19 and CD99 immunoexpression profile in goblet cell (mucin-producing neuroendocrine tumors) and classical carcinoids of the vermiform appendix. Int J Surg Pathol. 2007;15:252-257.
34. Goto A, Niki T, Terado Y, et al. Prevalence of CD99 protein expression in pancreatic endocrine tumours (PETs). Histopathology. 2004;45:384-392.
35. Llombart B, Monteagudo C, Lopez-Guerrero JA, et al. Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers. Histopathology. 2005;46:622-634.
36. Pelosi G, Fraggetta F, Sonzogni A, et al. CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours. Virchows Arch. 2000;437:270-274.